Savara Inc. announced that Dave Lowrance, its Chief Financial and Administrative Officer, will step down on July 15, 2026, due to health reasons. The company will separate financial and administrative duties, with COO Robert Lutz assuming the CFO role. This leadership change aims to ensure smooth financial management as Savara advances its clinical-stage biopharmaceutical programs, including MOLBREEVI for rare respiratory diseases. The transition reflects the company's focus on strong governance and operational continuity.
The Taiwan Freedom Project has released a special 32-page section in The Washington Times titled "Why Taiwan Matters, Now More Than Ever," emphasizing Taiwan's critical geopolitical role and the threats it faces from China. The publication features b...
Bitcoin's realized profit and loss ratio among short-term holders has dropped to its lowest point in 43 months, with nearly half of its supply underwater, a pattern seen at previous cycle bottoms in 2012, 2014, 2019, and 2022. This capitulation phase...
A single whale wallet has accumulated $31.43 million in Ethereum (ETH) and $6.24 million in Wrapped Bitcoin (WBTC), totaling $37.67 million. This move shows significant diversification across the two largest crypto networks, combining native ETH and ...
Pepe (PEPE), a meme-inspired cryptocurrency, surged 12.16% to $0.000003, reaching a market cap of $1.16 billion driven by community initiatives and social media attention. Other notable gainers include Cronos (CRO) up 7.79%, Cardano (ADA) rising 7.27...
The Québec Superior Court has approved a restructuring transaction for Premier Health of America Inc., allowing the company to continue uninterrupted operations. The deal involves the acquisition of three affiliates by Polar Valley Investments Limite...
